 AUSTIN, Texas, Feb. 17, 2021 GLOBE NEWSWIRE -- Molecular Templates, Inc. Nasdaq: MTEM the Company or Molecular, a clinical-stage biopharmaceutical company focused on the discovery and development of the Companys proprietary engineered toxin bodies ETBs, which are differentiated, targeted, biologic therapeutics for cancer and other serious diseases, today announced that it has commenced an underwritten public offering of its common stock. Molecular also intends to grant the underwriters a 30-day option to purchase up to an additional 15 of the shares of common stock offered in the public offering on the same terms and conditions. All of the shares in the offering are to be sold by Molecular. 